Peru’s Lambda variant (Pango lineage C.37) of the Covid virus has scientists puzzled as to its features and contagiousness.

The variant was first observed in Peru at the end of last year, has spread to most other countries in Latin America and beyond. Cases have recently been identified in the United Kingdom. In Peru, it accounts for around 80% of samples currently recorded in Peru’s third wave, according to scientists at the Cayetano Heredia University cited by the Financial Times.

The new variant has received the name ‘Lambda’ and is designated a ‘variant of interest’ by the WHO and ‘variant under investigation’ by Public Health England last month. The ‘variants of concern’ – Alpha, Beta, Gamma and Delta – were first noted in the UK, South Africa, Brazil and India respectively. Other ‘variants of interest’ are from Epsilon through to Kappa.

According to scientists, it has an unusual set of mutations that distinguishes it from other mutations. So far, the extent to which this new variant is more contagious than others remains unclear.

The third wave of Coronavirus continues to place strain on the Peruvian health system, just as it is doing throughout much of Latin America. Apart from Paraguay and Venezuela, Peru is the Latin American country that has vaccinated the least number of its citizens for the first dose, just 13% according to Our World in Data by 28 June. This is lower than in Ecuador or Bolivia. Those receiving two doses account for 8.9% of the population.

The distribution of vaccinations has proved highly unequal so far with much higher rates in Lima and Callao than in the rest of the country. Health Minister Oscar Ugarte has promised to distribute more to people living outside Lima. However, in some areas regional authorities have encountered difficulty in distributing existing stocks, especially to people living in rural areas.

The government expects delivery of 7.9 million doses during July, 3.4 million from Pfizer 4 million from Sinopharm and 500,000 from COVAX (Astra Zeneca).